Abstract
Aim: to evaluate the efficacy and safety of Kolofort® in the treatment of patients with moderate to mild irritable bowel syndrome (IBS). Patients and Methods: an open cohort prospective placebo-controlled study was conducted with the inclusion of 30 patients (average age 30.7±7.8 years) with an established diagnosis of IBS. The control group consisted of 10 healthy subjects. Kolofort® was prescribed for a course of 12 weeks, 2 tablets 2 times a day. All patients were evaluated before and after the therapy course for the main clinical symptoms of IBS, as well as the severity of anxiety and depression, the level of specific anxiety regarding GIT symptoms and life quality. Cortisol levels in the morning and evening portions of saliva were determined in healthy subjects and patients with IBS. Results: initially, patients with IBS had a high level of anxiety and depression, a high index of visceral hyperssensitivity, and a low life quality. In patients with IBS, the cortisol level in the morning and evening portions of saliva before treatment was statistically significantly higher than in healthy subjects (in both cases, p<0,05). After 12 weeks of therapy, there was a statistically significant decrease in the severity of clinical manifestations of the disease (p<0,05), in the severity of depression, anxiety, visceral hypersensitivity and an increase in the life quality. After the therapy course, patients with IBS noted a significant decrease in the cortisol level in the morning and evening portions of saliva. During therapy, 3 adverse events were registered: headache (n=2), nausea (n=1), which did not require drug discontinuation. Conclusion: the efficacy of Kolofort® in the treatment of patients with IBS with a moderate and mild disease course, both in relation to the main GIT symptoms and concomitant psychoemotional disorders, has been shown. Good efficacy and tolerability of the drug ensured high patient adherence to the treatment. KEYWORDS: irritable bowel syndrome, cortisol, stress, Kolofort, visceral hyperssensitivity, anxiety. FOR CITATION: Livzan M.A., Gaus O.V. New methods to the patient management with irritable bowel syndrome. Russian Medical Inquiry. 2021;5(6):391–397 (in Russ.). DOI: 10.32364/2587-6821-2021-5-6-391-397.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
